Michael Schmitz
Stock Analyst at Guggenheim
(3.02)
# 1,275
Out of 5,154 analysts
8
Total ratings
71.43%
Success rate
69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $15.47 | -67.68% | 1 | Nov 14, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $27.06 | +58.91% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $41.55 | +8.32% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $98.40 | -16.67% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $13.60 | +194.12% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.33 | - | 1 | Jan 3, 2023 | |
| APC ARKO Petroleum | Initiates: Buy | $85 | $18.72 | +354.06% | 1 | Dec 19, 2016 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $15.47
Upside: -67.68%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $27.06
Upside: +58.91%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $41.55
Upside: +8.32%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $98.40
Upside: -16.67%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $13.60
Upside: +194.12%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.33
Upside: -
ARKO Petroleum
Dec 19, 2016
Initiates: Buy
Price Target: $85
Current: $18.72
Upside: +354.06%